Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Jan 13;100(1):19-23.
doi: 10.1038/sj.bjc.6604784. Epub 2008 Nov 18.

Molecular therapy for the treatment of hepatocellular carcinoma

T F Greten  1 , F Korangy, M P Manns, N P Malek
Affiliations
Review

Molecular therapy for the treatment of hepatocellular carcinoma

T F Greten et al. Br J Cancer. .

Abstract

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide. Conventional cytotoxic chemotherapy has failed to show a substantial benefit for patients with HCC. Recently, a number of new drugs targeting molecular mechanisms involved in liver cell transformation have entered into clinical trials and led to encouraging results. In this review we summarise this data and point to a number of new compounds, which are currently being tested and can potentially broaden our therapeutic arsenal even further.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic overview of key pathways in carcinogenesis and molecularly targeted therapy in hepatocellular carcinoma.
See this image and copyright information in PMC

References

    1. Abou-Alfa GK, Johnson P, Knox J, Davidenko I, Lacava J, Leung T, Mori A, Le Berre M, Voliotis D, Saltz L (2008) Final results from a phase II (PhII), randomized, double-blind study of sorafenib plus doxorubicin (S+D) versus placebo plus doxorubicin (P+D) in patients (pts) with advanced hepatocellular carcinoma. In 2008 Gastrointestinal Cancers Symposium Abstract 128. American Society of Oncology, 25–27 January 2008, Orlando, FL, USA, p132
    1. Alberts SR, Morlan BW, Kim GP, Pitot HC, Quevedo FJ, Dakhil SR, Gross HM, Merchan JR, Roberts RL (2007) NCCTG phase II trial (N044J) of AZD2171 for patients with hepatocellular carcinoma (HCC) – Interim review of toxicity. In Gastrointestinal Cancers Symposium Abstract 186. American Society of Oncology, 19–21 January 2007, Orlando, FL, USA, p178
    1. Cheng A, Kang Y, Chen Z, Tsao C, Qin S, Kim J, Burock K, Zou J, Voliotis D, Guan ZZ (2008) Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma. J Clin Oncol 26: 4509. - PubMed
    1. El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557–2576 - PubMed
    1. Faivre SJ, Raymond E, Douillard J, Boucher E, Lim HJ, Kim JS, Lanzalone S, Lechuga MJ, Sherman L, Cheng A (2007) Assessment of safety and drug-induced tumor necrosis with sunitinib in patients (pts) with unresectable hepatocellular carcinoma (HCC). J Clin Oncol 25: 3546

Publication types

MeSH terms